Successful Targeted Injectable Chemotherapy Treatment for Dogs Could Lead to Human Trials
University of Kansas Cancer CenterResearchers are studying a new injectable chemo that has shown to be successful in canines.
Researchers are studying a new injectable chemo that has shown to be successful in canines.
Jennifer Klemp, PhD, MPH, director of cancer survivorship and an associate professor at The University of Kansas Cancer Center, is interviewed by Oncology Nursing News. In this interview, Klemp offers insights on some of the critical issues that clinicians face, among them: how to deliver optimal survivorship care, what ingredients go into the plan, how to measure progress, and how is this care reimbursed.
Currently, excess body weight contributes to as many as 1 in 5 cancer-related deaths. Obesity is associated with increased risk of at least eight types of cancer. The American Society of Clinical Oncology has identified obesity as a health risk that is “quickly overtaking tobacco as the leading preventable cause of cancer.”
Allen M. Chen, M.D., has been appointed the new Joe and Jean Brandmeyer Chair of the Department of Radiation Oncology at the University of Kansas School of Medicine. He will join the faculty on October 1, 2016.
Dr. Carol Fabian honored for her work changing the odds for women with breast cancer and those at increased risk for the disease.
Yoshiaki Azuma, Ph.D., is analyzing the role of enzyme Topo II and how its functions may show how cancer mutations are born.
KU Cancer Center researchers Liang Xu, Ph.D., and Kristi Neufeld, Ph.D. are studying gossypol, a natural compound currently going through early phase clinical trials for prostate cancer.
NIH grant will help create Kansas PKD Research and Translation Core Center
Trial trains patients' re-engineered cells to chase down the cancer and destroy it
Trials trains patients' re-engineered cells to chase down the cancer and destroy it
A team of researchers led by KU Cancer Center Cancer Prevention & Survivorship Program member, Animesh Dhar, Ph.D., found that crocetinic acid, a purified compound from crocetin, showed the inhibition of growth in human pancreatic cancer cells grown either in a dish or as tumors under the skin of mice.
Clinical trial improves outcomes with safer, more effective therapy
Priyanka Sharma, M.D., is looking at what she’s calling “BRCAness” or deficiency in DNA damage repair machinery in triple-negative breast cancer as a potential prognostic and predictive marker.
A new study of a biomarker that can identify DCIS patients who are not at risk for subsequent invasion could save many lives and keep women from having to go through medical and surgical therapy.
Understanding how these organisms trigger the transformation of normal cells to cancerous ones is the focus of a new National Cancer Institute grant awarded to Shahid Umar, Ph.D., of The University of Kansas Cancer Center.
KU Cancer Center researcher is finding out why ovarian cancer is resistant to certain types of chemo to eventually identify a different drug target.
The University of Kansas Cancer Center’s Bone Marrow Transplant program is participating in a nationwide clinical trial that analyzes outcomes after two common treatments: bone marrow transplant and chemotherapy. The results could lead to wider access to transplants.
KU Cancer Center physician is studying an alternative method to quitting smoking for people who have chronic obstructive pulmonary disease (COPD) without requiring them to attempt to quit abruptly.
KU Cancer Center researcher is using genomic, transcriptomic and epigenomic data to determine cancer molecular subtypes.
Allen Greiner, MD, MPH, and his team are using something called "implementation intentions" questions to determine what will help people get screened for colorectal cancer. The results were published in a recent issue of the American Journal of Preventive Medicine.
KU Cancer Center physician is leading a study for women with a higher risk of breast cancer that focuses on two natural approaches to preventing breast cancer: weight loss and omega-3 fatty acids EPA and DHA.
Statistical prediction models could help doctors determine when non-invasive bladder cancer will return.
New research technique could allow better, more personalized cancer drug treatments
KU Cancer Center researchers have identified a protein that could prevent metastasis and recurrence of breast cancer.
Unexpected results from an ongoing experiment in the lab of Kristi Neufeld, Ph.D., co-leader of the Cancer Biology Program, led to a potentially important discovery that could have an impact on how cancer researchers test anti-cancer therapies in mice, and possibly prevent colon cancer in people.
KU Cancer Center Nanotex Phase I trial extends survival rate and is better tolerated for ovarian and other abdominal cancer patients.
New research underway at KU Cancer Center is focusing on the mutant version of the p53 tumor protein and how it is vulnerable to certain compounds.
KU Cancer Center researchers are working towards cutting off the growth of pancreatic tumors before they can metastasize throughout the body.
Researchers at the University of Kansas Medical Center will use a $1.5 million grant from the National Cancer Institute to examine ways to lower the rates of cervical cancer among incarcerated women. They also hope to answer key questions about sexual and reproductive health care for women with criminal justice histories, which is relatively understudied in medical research.
One of the ways the KU Cancer Center leads our region in cancer research is through clinical trials. Two stage IV cancer patients currently enrolled in KU Cancer Center clinical trials share their personal stories of why they got involved in cancer research.
Osteosarcoma is the most common bone tumor among children and young adults, with about 400 cases diagnosed in the United States each year, with five-year survival rates between 50 and 60 percent. With the help of dogs, researchers at the University of Kansas Cancer Center, Children's Mercy and Colorado State University will screen thousands of drugs in a new project that seeks to improve the treatment of this rare bone cancer in humans and dogs alike.
Findings provide a direct proof for a new therapy and provide hope for the people with this disease
HylaPharm's patented technology delivers chemotherapy drugs directly to cancer cells in tumors and nearby lymph nodes while limiting drug exposure in kidneys, nerves and auditory organs.
Adenomatous polyposis coli is critical in protecting against colon cancer. KU Cancer Center researchers have shown that APC stationed in the nucleus is necessary to suppress Wnt and its signaling partners.
Researchers at the University of Kansas Medical Center found that a combination of infused vitamin C and conventional chemotherapy stopped ovarian cancer in the laboratory, and reduced chemotherapy-associated toxicity in patients with ovarian cancer.
Aside from the 2013 Nobel Prize in Medicine going to the discoverers of this highly organized transport system, scientific interest in a particular group of vesicles called exosomes has accelerated over the last several years. Andrew K. Godwin, Ph.D., professor and director of molecular oncology at the University of Kansas Medical Center, is among the researchers studying the potential clinical applications of these specialized structures.
Researchers at the University of Kansas Medical Center will use more than $10 million from the new Patient-Centered Outcomes Research Institute (PCORI) to conduct three projects that will help deliver new cures and therapies to patients faster. PCORI is an independent organization authorized by the U.S. Congress in 2010 as part of the Patient Protection and Affordable Care Act.